Statera Biopharma (NASDAQ:STAB) Trading 2.2% Higher

Shares of Statera Biopharma, Inc. (NASDAQ:STABGet Rating) traded up 2.2% during trading on Thursday . The stock traded as high as $0.25 and last traded at $0.24. 683,816 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 4,698,053 shares. The stock had previously closed at $0.24.

The business has a fifty day simple moving average of $0.25 and a 200-day simple moving average of $0.90. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.17.

Several large investors have recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. raised its position in shares of Statera Biopharma by 143.7% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 29,859 shares of the company’s stock worth $69,000 after purchasing an additional 17,609 shares during the period. BlackRock Inc. acquired a new position in shares of Statera Biopharma during the third quarter worth approximately $44,000. UBS Group AG purchased a new stake in Statera Biopharma in the 1st quarter valued at $37,000. Virtu Financial LLC raised its position in Statera Biopharma by 409.2% in the 1st quarter. Virtu Financial LLC now owns 157,678 shares of the company’s stock valued at $50,000 after buying an additional 126,715 shares during the last quarter. Finally, Northern Trust Corp raised its position in Statera Biopharma by 335.9% in the 1st quarter. Northern Trust Corp now owns 171,110 shares of the company’s stock valued at $54,000 after buying an additional 131,855 shares during the last quarter. 8.43% of the stock is currently owned by institutional investors.

About Statera Biopharma (NASDAQ:STAB)

Statera BioPharma, Inc, a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.

See Also

Receive News & Ratings for Statera Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Statera Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.